Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo

Despite improvement in the treatment of medulloblastoma over the last years, numerous patients with MYC- and MYCN-driven tumors still fail current therapies. Medulloblastomas have an intact retinoblastoma protein RB, suggesting that CDK4/6 inhibition might represent a therapeutic strategy for which...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonchere, Barbara, Williams, Justin, Zindy, Frederique, Liu, Jingjing, Robinson, Sarah, Farmer, Dana M., Min, Jaeki, Yang, Lei, Stripay, Jennifer L., Wang, Yingzhe, Freeman, Burgess B., Yu, Jiyang, Shelat, Anang A., Rankovic, Zoran, Roussel, Martine F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808370/
https://www.ncbi.nlm.nih.gov/pubmed/36318650
http://dx.doi.org/10.1158/1535-7163.MCT-21-0896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808370/
https://www.ncbi.nlm.nih.gov/pubmed/36318650
http://dx.doi.org/10.1158/1535-7163.MCT-21-0896

Ejemplares similares